Life · Medicine · Pharma · Stocks

CLINICAL TRIALS : COVID-19

Phase 3 trials of Favipiravir by Glenmark shows faster time to improvement in mid to moderate COVID19 patients

Claim is “no serious adverse effects seen” which is positive